Shots:

• CRISPR to get direct management of Casebia Therapeutics- which would focus on developing lead programs in hemophilia- ophthalmology and autoimmune diseases. Bayer to get an option for two products at IND submission
• In Dec’2015- Bayer and CRISPR collaborated to create JV (Casebia) for the discovery- development & commercialization of breakthrough therapies to cure blood disorders- blindness- and congenital heart disease- combining CRISPR-Cas9 gene-editing technology & IP with Bayer’s protein engineering expertise
• CRISPR will advance the Casebia’s programs to the next phase of development with its expected transaction to be closed in Q4’19

Click here to­ read full press release/ article | Ref: CRISPR Therapeutics | Image: PRNewswire